CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
Rhea-AI Summary
CytoSorbents (NASDAQ: CTSO) reported second quarter 2026 revenue of $9.6 million, flat year over year, with gross margin improving to 73% from 71% a year ago and 69% in Q1 2026. Operating loss narrowed 27% to $2.6 million. Net loss was $4.4 million, or $0.07 per share, versus net income of $1.9 million, or $0.03 per share, in Q2 2025, mainly due to non-cash foreign currency translation effects. Adjusted net loss improved 22% to $2.8 million, while adjusted EBITDA loss improved 38% to $1.6 million.
Total cash, cash equivalents, and restricted cash were $5.9 million at June 30, 2026, with quarterly cash burn reduced to $0.4 million, including $0.2 million of restructuring payments. The company highlighted four value drivers: achieving operating cash flow breakeven, returning the CytoSorb business to profitable growth, securing FDA approval for DrugSorb-ATR to open the U.S. market, and unlocking strategic options for HemoDefend-BGA following recent FDA feedback and prior $16 million in non-dilutive funding.
Positive
- Gross margin 73% in Q2 2026, up from 71% a year ago and 69% in Q1 2026
- Operating loss $2.6 million, a 27% improvement from $3.6 million in Q2 2025
- Adjusted EBITDA loss $1.6 million, improving 38% from a $2.6 million loss in Q2 2025
- Operating cash burn about $0.2 million in Q2 2026 excluding approximately $0.2 million in restructuring payments
- Distributor and strategic partner sales up 16% in Q2 2026 despite geopolitical disruption in the Middle East
- Workforce reduced about 23% since September 2025, contributing to lower operating costs and a leaner organization
Negative
- Revenue $9.6 million in Q2 2026 was unchanged from Q2 2025, indicating no topline growth
- Germany sales decreased 24% in Q2 2026, offsetting 16% distributor and 9% non-Germany direct growth
- Net loss $4.4 million, or $0.07 per share, compared with net income of $1.9 million, or $0.03 per share, in Q2 2025
- Total cash $5.9 million at June 30, 2026, down from $6.3 million at March 31, 2026
- Company not yet in compliance with Nasdaq listing requirements and intends to regain compliance in the near future
News Explained
DrugSorb-ATR remains unapproved; its U.S. market opportunity depends on August FDA meetings, requested testing, and a planned early-2027 submission.
The company reported second-quarter results and presented DrugSorb-ATR as a route to opening the U.S. market, but it also states the device is not yet approved in the United States or Canada; the commercial opportunity therefore remains contingent on regulatory progress.
The next disclosed steps are
For HemoDefend-BGA, product development is complete and the company received constructive FDA feedback in
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Q1 earnings report | Negative | -5.0% | Revenue rose, but net loss widened amid foreign-currency effects and liquidity concerns. |
| Mar 25 | Q4 earnings report | Positive | -10.6% | Revenue and margins improved; amended credit facility added $2.5M financing support. |
| Nov 13 | Q3 earnings report | Positive | -0.8% | Revenue and operating loss improved, alongside cost reductions and financing. |
| Aug 07 | Q2 earnings report | Positive | +12.0% | Revenue grew, net income improved, and FDA regulatory developments remained active. |
| May 14 | Q1 earnings report | Negative | +3.3% | Revenue declined and FDA denied the De Novo request despite improved losses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were mixed, with both positive and negative responses across the prior five earnings events.
Key Terms
adjusted EBITDA financial
De Novo application regulatory
DOACs medical
CABG medical
non-dilutive funding financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Highlighting Four Independent Drivers of Shareholder Value
Second Quarter 2026 Financial Results
- Revenue was
$9.6 million - Gross margin improved to
73% in the quarter, up sequentially from69% in Q1 2026 and from71% a year ago. - Operating loss improved by
27% to$2.6 million $3.6 million - Net loss was
$4.4 million $0.07 $1.9 million $0.03 - Adjusted net loss, which excludes the impact of non-cash changes in foreign currency translations and non-cash stock compensation, improved by
22% to$2.8 million $0.05 $3.7 million $0.06 - Adjusted EBITDA loss, which also excludes the impact of non-cash changes in foreign currency translations and non-cash stock compensation improved by
38% to$1.6 million $2.6 million - Total cash, cash equivalents, and restricted cash was approximately
$5.9 million $6.3 million - Total cash burn in the second quarter was reduced to
$0.4 million $0.2 million
"Second quarter revenue performance was led by strong growth in our distributor and strategic partner territories, as well as direct sales outside of
Over the past couple of years, our priorities have been clear. We have needed to strengthen the financial foundation of the Company, improve commercial and operating execution, advance our regulatory programs, and position the business for sustainable long-term growth. During the second quarter, we continued making meaningful progress against each of these objectives. While we are not yet where we want to be, we believe CytoSorbents today is better positioned for success than it was a year ago.
Four Independent Value Drivers
Looking ahead, we believe CytoSorbents has strong value creation opportunities. We believe we have four independent value drivers over the next six to eighteen months and that each has the potential to strengthen the business and create meaningful long-term shareholder value by reducing risk, expanding profitability, opening new markets, and unlocking strategic value.
First Value Driver: Achieving Operating Cash Flow Breakeven
Our first value driver is reducing financial risk by achieving sustainable operating cash flow breakeven.
Over the past year, we have focused relentlessly on improving the economics of our business. Product gross margin improved to
As a result, operating cash burn declined to approximately
We believe this milestone is important because it fundamentally changes the Company's financial profile. Every dollar of operating cash burn eliminated reduces future financing needs, strengthens our balance sheet, increases strategic flexibility, and allows a greater proportion of future growth to accrue to shareholders. Although important work remains, we believe the progress achieved over the past year demonstrates that this strategy is working."
Second Value Driver: Returning the CytoSorb Business to Sustainable, Profitable Growth
Our second value driver is returning our core CytoSorb business to sustainable, profitable growth.
Although overall revenue growth remains modest today, the majority of the business did well during the second quarter, with
At the same time, our messaging and training of treating the "Right Patient, at the Right Time, with the Right Dose" continues to resonate with customers. This is partially evident in the increasing customer adoption of our PuriFi® pump platform and HotSwap® technology which have been received very well. These technologies simplify therapy delivery, encourage earlier and more intensive intervention, and promote more consistent utilization of CytoSorb.
We believe these and other initiatives, particularly the operational investments and commercial restructuring completed over the past year, have positioned us for greater sales effectiveness that can strengthen both clinical adoption and long-term profitable growth of the franchise.
Third Value Driver: Opening the
Our third value driver is obtaining FDA marketing approval for DrugSorb-ATR and opening what we believe represents one of the Company's most important long-term growth opportunities.
DrugSorb-ATR addresses a significant unmet need in cardiac surgery by removing commonly prescribed blood thinners during cardiopulmonary bypass for patients requiring urgent surgery. With the positive results of the STAR-T trial in CABG patients now published and the growing body of real-world evidence using our therapies for the anti-platelet drug Brilinta® and the direct oral anticoagulants, Eliquis® and Xarelto®, we are confident in the worldwide potential of our technologies for this application. In the
During August, we have two important FDA pre-submission meetings scheduled. The first is to discuss options to generate additional mechanistic data requested by FDA for our Brilinta® program. Following this meeting, we intend to finalize and confirm the testing protocol with FDA, which may require an additional meeting with the Agency. Once finalized, we anticipate completing the required testing, and submitting a new De Novo application in early 2027 that will include these data and new real-world clinical evidence analyses involving four times the number of coronary artery bypass graft (CABG) patients on Brilinta® treated with DrugSorb-ATR, compared to the original STAR-T trial.
In the second scheduled meeting, we will present our data to the FDA supporting a potential parallel De Novo submission for DrugSorb-ATR in patients receiving direct oral anticoagulants, or DOACs, and discuss what additional information, if any, the Agency believes is necessary.
We believe these meetings will provide additional clarity toward FDA marketing authorization. Successful marketing approval would establish a second commercial franchise alongside our international CytoSorb business, open access to the world's largest healthcare market, further validate our adsorption technology platform, increase our gross margins and potential profitability, and create opportunities for future expansion.
Fourth Value Driver: Unlocking the Strategic Value of HemoDefend-BGA
Our fourth value driver is realizing the strategic value of HemoDefend-BGA - a technology that we believe is not fully reflected in today's valuation.
Developed with approximately
The technology has the potential to simplify blood inventories, reduce waste, lower costs, and improve access to life-saving blood products. Leading blood centers have helped to evaluate and validate the technology, and we believe its commercial potential extends well beyond today's blood banking model.
As one example, imagine the simplification and cost savings to hospital blood banks from currently maintaining 4 types of plasma (A, B, AB, O) and 4 types of platelets to now just 1 universal plasma and 1 universal platelet product. Or picture a future where every ambulance, first responder, or military vehicle around the world carries freeze-dried universal plasma on board - without refrigeration, without the need to blood type, and ready for immediate transfusion to patients suffering severe trauma and life-threatening hemorrhage. We believe HemoDefend-BGA has the potential to help make that future possible.
Over the past year, we completed product development, and in July 2026 we received constructive FDA feedback regarding our anticipated clinical pathway following a pre-submission interaction with the Agency. In addition, we continue to have encouraging discussions with
While our immediate priorities remain achieving operating cash flow breakeven, growing the CytoSorb franchise, and advancing DrugSorb-ATR, we believe HemoDefend-BGA represents a valuable strategic asset with multiple potential pathways to create shareholder value, including commercial partnerships, licensing opportunities, government funding, or other strategic alternatives.
Looking Ahead: Four Independent Value Drivers. One Uncommon Value.
Taken together, these four value drivers represent multiple independent opportunities to create value over the next 6 to 18 months.
- The first reduces financial risk by expanding operating margins, and achieving operating cash flow breakeven
- The second returns our core CytoSorb business to consistent, profitable growth,
- The third opens the U.S. market and establishes what we believe can become a second major commercial franchise
- And the fourth unlocks the value of a highly differentiated blood purification platform with meaningful strategic optionality
We believe each of these initiatives has the potential to independently strengthen our business and increase shareholder value. Together, they have the potential to fundamentally transform CytoSorbents into a stronger, more profitable, and more diversified medical technology company.
Dr. Chan concluded, "Although more work remains, we believe our accomplishments over the past several quarters have stabilized the company and have positioned it for this next phase, where our entire organization remains intensely focused on disciplined execution. In the near future, we intend to regain compliance with our Nasdaq listing requirements, broaden the awareness of our Company and our four separate value drivers, and secure the Company financially. We appreciate our shareholder's support and look forward to updating them as we continue to make progress on each of these important objectives."
Second Quarter 2026 Earnings Conference Call
CytoSorbents' management will host a live conference call, presentation webcast, and a question-and-answer session with the following information:
Date: Thursday, August 6, 2026
Time: 4:30 PM ET
Live webcast link: https://app.webinar.net/v62381bx4na
It is recommended that participants join approximately 10 minutes prior to the start of the call.
An archived recording of the conference call will be available under the Investor Relations section of the Company's website at https://ir.cytosorbents.com/
About DrugSorb-ATR
In the
The Company continues to actively pursue regulatory approval of DrugSorb-ATR with the FDA and expects to pursue regulatory approval in
About Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Share which excludes non-cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges from Net Loss and Net Loss Per Share, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by investors and the analyst community to help them analyze the performance of our business, the Company's cash available for operations, and the Company's ability to meet future capital expenditure and working capital requirements. For a reconciliation of non-GAAP financial measures to the most comparable GAAP measure, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.
CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United States.
In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.
The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, PuriFi®, HotSwap®, and others. For more information, please visit the Company's website at https://ir.cytosorbents.com/ or follow us on Facebook and X.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval, our ability to reduce costs, optimize operations, and achieve cash-flow break-even in the second half of 2026, our ability to appropriately finance the Company, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and X
U.S. Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
ir@cytosorbents.com
CYTOSORBENTS CORPORATION | ||||||
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | ||||||
(in thousands, except share data) | ||||||
June 30, | December 31, | |||||
2026 | 2025 | |||||
(unaudited) | ||||||
ASSETS | ||||||
Current Assets: | ||||||
Cash and cash equivalents | $ | 4,413 | $ | 6,249 | ||
Accounts receivable, net of allowances of | 6,786 | 7,550 | ||||
Inventories - net | 3,686 | 5,281 | ||||
Prepaid expenses and other current assets | 852 | 1,554 | ||||
Total current assets | 15,737 | 20,634 | ||||
Property and equipment - net | 7,172 | 7,823 | ||||
Restricted cash | 1,522 | 1,522 | ||||
Right-of-use asset | 10,612 | 10,924 | ||||
Patents - net | 2,864 | 3,226 | ||||
Other assets | 53 | 53 | ||||
Total assets | $ | 37,960 | $ | 44,182 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||
Current Liabilities: | ||||||
Accounts payable | $ | 2,002 | $ | 2,869 | ||
Accrued expenses and other current liabilities | 7,283 | 6,299 | ||||
Lease liability – current portion | 589 | 541 | ||||
Current maturities of long-term debt, net of debt discount | 14,149 | — | ||||
Total current liabilities | 24,023 | 9,709 | ||||
Lease liability, net of current portion | 11,596 | 11,903 | ||||
Long-term debt, net of current portion and debt discount | 3,092 | 16,667 | ||||
Total liabilities | 38,711 | 38,279 | ||||
Commitments and Contingencies | ||||||
Stockholders' equity (deficit) | ||||||
Preferred Stock, par value | — | — | ||||
Common Stock, par value | 63 | 63 | ||||
Additional paid-in capital | 321,936 | 321,024 | ||||
Accumulated other comprehensive loss | (996) | (2,977) | ||||
Accumulated deficit | (321,754) | (312,207) | ||||
Total stockholders' equity (deficit) | (751) | 5,903 | ||||
Total liabilities and stockholders' equity (deficit) | $ | 37,960 | $ | 44,182 | ||
See accompanying notes to condensed consolidated financial statements. | ||||||
CYTOSORBENTS CORPORATION | ||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||
(in thousands, except share and per share data) | ||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Revenue, net | $ | 9,633 | $ | 9,617 | $ | 18,497 | $ | 18,344 | ||||
Cost of goods sold | 2,584 | 2,803 | 5,318 | 5,323 | ||||||||
Gross profit | 7,049 | 6,814 | 13,179 | 13,021 | ||||||||
Operating expenses | ||||||||||||
Research and development, net of grant income | 1,453 | 1,262 | 2,478 | 2,924 | ||||||||
Selling, general and administrative | 7,964 | 9,167 | 16,073 | 17,599 | ||||||||
Restructuring | 270 | — | 310 | — | ||||||||
Total operating expenses | 9,687 | 10,429 | 18,861 | 20,523 | ||||||||
Loss from operations | (2,638) | (3,615) | (5,682) | (7,502) | ||||||||
Other income (expense) | ||||||||||||
Interest expense, net | (868) | (616) | (1,726) | (1,221) | ||||||||
Gain (loss) on foreign currency transactions | (911) | 6,178 | (2,139) | 9,192 | ||||||||
Total other income (expense), net | (1,779) | 5,562 | (3,865) | 7,971 | ||||||||
Net income (loss) | $ | (4,417) | $ | 1,947 | $ | (9,547) | $ | 469 | ||||
Basic net income (loss) per common share | $ | (0.07) | $ | 0.03 | $ | (0.15) | $ | 0.01 | ||||
Diluted net income (loss) per common share | $ | (0.07) | $ | 0.03 | $ | (0.15) | $ | 0.01 | ||||
Weighted Average Shares of Common Stock | ||||||||||||
Basic | 62,806,694 | 62,608,598 | 62,772,761 | 61,675,447 | ||||||||
Diluted | 62,806,694 | 67,166,377 | 62,772,761 | 66,255,298 | ||||||||
Other comprehensive income (loss): | ||||||||||||
Foreign currency translation adjustment, net of tax | 1,105 | (5,476) | 1,981 | (8,212) | ||||||||
Comprehensive loss | $ | (3,312) | $ | (3,529) | $ | (7,566) | $ | (7,743) | ||||
See accompanying notes to condensed consolidated financial statements. | ||||||||||||
CYTOSORBENTS CORPORATION | |||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) | |||||||||||||||||
(in thousands, except share data) | |||||||||||||||||
Accumulated | |||||||||||||||||
Additional | Other | ||||||||||||||||
Common Stock | Paid-In | Comprehensive | Accumulated | Stockholders' | |||||||||||||
Shares | Par Value | Capital | Loss | Deficit | Equity (Deficit) | ||||||||||||
For the three months ended June 30, 2026 | |||||||||||||||||
Balance as of March 31, 2026 (unaudited) | 62,733,305 | $ | 63 | $ | 321,568 | $ | (2,101) | $ | (317,337) | $ | 2,194 | ||||||
Stock-based compensation | — | — | 368 | — | — | 368 | |||||||||||
Common stock issued upon vesting of restricted stock | 109,443 | — | — | — | — | — | |||||||||||
Foreign translation adjustment | — | — | — | 1,105 | — | 1,105 | |||||||||||
Net loss | — | — | — | — | (4,417) | (4,417) | |||||||||||
Balance as of June 30, 2026 (unaudited) | 62,842,748 | $ | 63 | $ | 321,936 | $ | (996) | $ | (321,754) | $ | (751) | ||||||
For the six months ended June 30, 2026 | |||||||||||||||||
Balance as of December 31, 2025 | 62,804,305 | $ | 63 | $ | 321,024 | $ | (2,977) | $ | (312,207) | $ | 5,903 | ||||||
Stock-based compensation | — | — | 912 | — | — | 912 | |||||||||||
Reversal of excess RSU shares issued | (71,000) | — | — | — | — | — | |||||||||||
Common stock issued upon vesting of restricted stock | 109,443 | — | — | — | — | — | |||||||||||
Foreign translation adjustment | — | — | — | 1,981 | — | 1,981 | |||||||||||
Net loss | — | — | — | — | (9,547) | (9,547) | |||||||||||
Balance as of June 30, 2026 (unaudited) | 62,842,748 | $ | 63 | $ | 321,936 | $ | (996) | $ | (321,754) | $ | (751) | ||||||
Accumulated | |||||||||||||||||
Additional | Other | ||||||||||||||||
Common Stock | Paid-In | Comprehensive | Accumulated | Stockholders' | |||||||||||||
Shares | Par Value | Capital | Loss | Deficit | Equity | ||||||||||||
For the three months ended June 30, 2025 | |||||||||||||||||
Balance as of March 31, 2025 (unaudited) | 62,529,466 | $ | 63 | $ | 318,452 | $ | 1,516 | $ | (305,487) | $ | 14,544 | ||||||
Stock-based compensation | — | — | 571 | — | — | 571 | |||||||||||
Common stock issued upon vesting of restricted stock | 69,260 | — | — | — | — | — | |||||||||||
Shares issued for exercise of stock options | 11,650 | — | — | — | — | — | |||||||||||
Foreign currency translation adjustment, net of tax | — | — | — | (5,476) | — | (5,476) | |||||||||||
Net income | — | — | — | — | 1,947 | 1,947 | |||||||||||
Balance as of June 30, 2025 (unaudited) | 62,610,376 | $ | 63 | $ | 319,023 | $ | (3,960) | $ | (303,540) | $ | 11,586 | ||||||
For the six months ended June 30, 2025 | |||||||||||||||||
Balance as of December 31, 2024 | 54,830,146 | $ | 55 | $ | 310,809 | $ | 4,252 | $ | (304,009) | $ | 11,107 | ||||||
Stock-based compensation | — | 1 | 1,390 | — | — | 1,391 | |||||||||||
Common stock issued upon vesting of restricted stock | 101,581 | — | — | — | — | — | |||||||||||
Shares issued for exercise of stock options | 11,650 | — | — | — | — | — | |||||||||||
Issuance of common stock and warrants from rights | 6,249,791 | 6 | 5,386 | — | — | 5,392 | |||||||||||
Issuance of common stock from exercise of warrants | 1,417,208 | 1 | 1,438 | — | — | 1,439 | |||||||||||
Foreign translation adjustment | — | — | — | (8,212) | — | (8,212) | |||||||||||
Net income | — | — | — | — | 469 | 469 | |||||||||||
Balance as of June 30, 2025 (unaudited) | 62,610,376 | $ | 63 | $ | 319,023 | $ | (3,960) | $ | (303,540) | $ | 11,586 | ||||||
See accompanying notes to condensed consolidated financial statements. | |||||||||||||||||
CYTOSORBENTS CORPORATION | |||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) | |||||||||||||
(in thousands) | |||||||||||||
Six | Six | ||||||||||||
Months Ended | Months Ended | ||||||||||||
June 30, | June 30, | ||||||||||||
2026 | 2025 | ||||||||||||
Cash flows from operating activities | |||||||||||||
Net income (loss) | $ | (9,547) | $ | 469 | |||||||||
Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||||||||||||
Amortization of debt discount | 573 | 381 | |||||||||||
Amortization of patents | 123 | 124 | |||||||||||
Depreciation and amortization | 576 | 649 | |||||||||||
Amortization of right-of-use asset | 53 | 72 | |||||||||||
Loss on abandoned patents | 338 | — | |||||||||||
Write-off of inventory | — | 253 | |||||||||||
Bad debt expense (recovery) | 240 | 9 | |||||||||||
Stock-based compensation | 912 | 1,391 | |||||||||||
Foreign currency transaction (gains) losses | 2,139 | (9,192) | |||||||||||
Changes in operating assets and liabilities | |||||||||||||
Accounts receivable | 377 | 257 | |||||||||||
Inventories | 1,512 | (925) | |||||||||||
Prepaid expenses and other current assets | 645 | 1,897 | |||||||||||
Other assets | 1 | — | |||||||||||
Accounts payable and accrued expenses | 313 | (360) | |||||||||||
Net cash used in operating activities | (1,745) | (4,975) | |||||||||||
Cash flows from investing activities | |||||||||||||
Purchases of property and equipment | (25) | (39) | |||||||||||
Disposals of property and equipment | 85 | — | |||||||||||
Payments for patent costs | (99) | (140) | |||||||||||
Net cash used in investing activities | (39) | (179) | |||||||||||
Cash flows from financing activities | |||||||||||||
Cash for exercise of warrants, net | — | 1,439 | |||||||||||
Proceeds from rights offering, net | — | 5,392 | |||||||||||
Net cash provided by financing activities | — | 6,831 | |||||||||||
Effect of exchange rates on cash | (52) | 285 | |||||||||||
Net change in cash, cash equivalents, and restricted cash | (1,836) | 1,962 | |||||||||||
Cash, cash equivalents, and restricted cash as of beginning of period | 7,771 | 9,764 | |||||||||||
Cash, cash equivalents, and restricted cash as of end of period | $ | 5,935 | $ | 11,726 | |||||||||
Supplemental disclosure of cash flow information | |||||||||||||
Cash paid for interest | $ | 1,215 | $ | 1,018 | |||||||||
Supplemental disclosure of non-cash financing activities | |||||||||||||
Fair value of common stock warrants issued in connection with the rights offering | $ | — | $ | 556 | |||||||||
See accompanying notes to condensed consolidated financial statements. | |||||||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-reports-second-quarter-2026-financial-results-recent-business-highlights-and-regulatory-update-302845431.html
SOURCE Cytosorbents Corp